Last reviewed · How we verify

NCT03629938

Evaluation and Classification of Foot Medial Longitudinal Arch Height in Adults

Completed Last updated 29 July 2020
What this trial tests

trial testing evaluation in Pes Planus in 350 participants. Completed in 28 May 2019.

Timeline
3 March 2019
Primary endpoint
14 April 2019
28 May 2019

Quick facts

Lead sponsorIstanbul Medipol University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment350
Start date3 March 2019
Primary completion14 April 2019
Estimated completion28 May 2019
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Medipol University Hospital

Who can join

Adults 18 to 40, any sex, with Pes Planus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is, to evaluate and classificate the medial longitudinal arch height in adult individuals. Aged between 18-40 years,350 adults who are voluntarily participate is going to be evaluate with Feiss Line(FL), Navicular Drop(ND) and Longitudinal Arch Angle(LAA) in subtalar neutral and resting position. Maximum, minimum values are going to be calculated. The 95% and 68% prediction intervals will be used as cut off limits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of evaluation

Trials testing the same drug.

Other recruiting trials for Pes Planus

Currently open trials in the same condition.

Other Istanbul Medipol University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03629938.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing